Search Results
Your search for 3 matches 15623 pages
Showing 6001 - 6050Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the antibody-drug conjugate belantamab mafodotin-blmf was granted accelerated approval for treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, ...
Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
On July 7, 2020, an oral combination of the nucleoside metabolic inhibitor decitabine and the cytidine deaminase inhibitor cedazuridine was approved for treatment of adult patients with myelodysplastic syndromes (MDS), including: Previously treated and untreated, de novo, and secondary MDS with the ...
Research Pioneer Marc L. Citron, MD, Establishes Grants Through Conquer Cancer
“Ask any doctor why he or she enters medicine and the answer will likely be the same,” said Marc L. Citron, MD. “People become doctors to help patients...but to deliver the moments that matter to patients—to extend their lives and give quality to their days—doctors rely on new research.” In 2003,...
Global Oncology Young Investigator Award: Early Support Improves Cancer Care Around the World
Global oncology refers to the application of the concepts of global health to cancer and implies an approach to the practice of oncology that acknowledges the reality of limited resources in parts of the world. The Global Oncology Young Investigator Award (YIA) from ASCO and Conquer Cancer, the...
Fitness-Based Treatment of Older Adults With Multiple Myeloma Who Are Transplant-Ineligible: The Changing Landscape
Multiple myeloma is a malignant clonal plasma cell malignancy that primarily affects older adults. Although therapeutic advances have led to improvements in disease-specific and overall survival over the past decade, age-related survival disparities continue to exist. The higher prevalence of...
Atezolizumab Plus Cobimetinib/Vemurafenib in BRAF V600–Positive Unresectable or Metastatic Melanoma
On July 30, 2020, atezolizumab was granted approval for use in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation–positive unresectable or metastatic melanoma.1,2 Supporting Efficacy Data Approval was based on findings from the phase III, double-blind IMspire150 trial ...
Three Scientists at Johns Hopkins Tapped to Join Exclusive Research Network
Among the first 45 members selected to join the 10x Genomics Visium Clinical Translational Research Network are 3 scientists from Johns Hopkins Kimmel Cancer Center. The organization is aimed at advancing translational research in some of the world’s leading health problems, including oncology,...
Setting an Ambitious Path to Ensure Health Equity for All Patients With Cancer
In keeping with her Presidential theme of “Equity: Every Patient, Every Day, Everywhere,” in July, ASCO President Lori J. Pierce, MD, FASTRO, FASCO, announced the Society was joining forces with the Association of Community Cancer Centers (ACCC) to increase racial and ethnic minority participation...
Avelumab in Maintenance Treatment of Urothelial Carcinoma
On June 30, 2020, avelumab was approved for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.1,2 Supporting Efficacy Data Approval was based on findings in the randomized, multicenter, ...
PROfound Trial Evaluates Olaparib in Homologous Recombination Repair Gene–Mutant Prostate Cancer
In a phase III trial (PROfound) reported in The New England Journal of Medicine, Johann de Bono, MB, ChB, PhD, of the Institute of Cancer Research and Royal Marsden Hospital, London, and colleagues found that olaparib significantly improved progression-free survival vs hormonal therapy in patients...
Art in Oncology: How Patients Add Life to Their Days
The ASCO Post is pleased to reproduce installments of “Art of Oncology” as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer. They include narratives, topical essays, historical...
High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...
Primary Prevention Strategies for Avoiding Cardiotoxicity in Patients With Cancer: A Growing Area of Research
Cancer is not for the faint of heart, and sometimes neither is the treatment, according to information presented during the ASCO20 Virtual Education Program.1 Approximately 30% of patients who receive cancer therapy will have cardiovascular complications.2 What’s more, in anthracycline-treated...
Update on Novel Immunotherapies for Plasma Cell Disorders
In this installment of The ASCO Post’s Hematology Expert Review, we take a closer look at the monoclonal antibody targeting CD38, daratumumab, in the treatment of amyloid light chain (AL) amyloidosis and resistant multiple myeloma as well as the antibody-drug conjugate belantamab mafodotin-blmf,...
Personalized Medicine Meets Geriatric Oncology: Tailoring Oncologic Care for Older Adults
The ASCO20 Virtual Scientific Program was a landmark year for the field of geriatric oncology, featuring more than 300 research abstracts that presented data on older adults with cancer. Here, we discuss several high-impact studies investigating interventions that modify outcomes for this patient...
Mobilizing to Meet Challenges and Improve Survival for COVID-19–Positive Patients and Health-Care Professionals
Recognizing the COVID-19 crisis “as an opportunity to mobilize the organization to rise in the most difficult challenges” allowed The University of Texas MD Anderson Cancer Center, Houston, to keep mortality rates low for COVID-19–positive patients with cancer and its employees. So said Peter WT...
Growing Body of Evidence Supports Adjuvant Immunotherapy for Stage IV Melanoma With No Evidence of Disease
With incredibly paced approvals and clinical advancements in the systemic therapy of cutaneous melanoma, the efficacy of immunotherapy in this disease is clear. However, many important questions remain regarding timing and dosing—in other words, which drug (or drugs) makes the most sense and in...
Ensartinib Doubles Progression-Free Survival in ALK-Positive NSCLC, Phase III Trial Reports
A potent, a next-generation ALK inhibitor has demonstrated promising efficacy in the first-line treatment of patients with advanced ALK-positive non–small cell lung cancer (NSCLC), according to data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference...
At Last: Targeting KRAS-Mutated Tumors ‘Is Now a Reality’
KRAS G12C inhibitors—which at this point include AMG 510 (now labeled sotorasib) and MRTX849—are proving to be active in KRAS G12C–mutated tumors, especially non–small cell lung cancer (NSCLC). KRAS G12C is a newly “druggable” target, joining what is still a limited list of some 3,000 potential...
Expert Point of View: Dean A. Fennell, FRCP, PhD
Invited discussant of the CheckMate 743 trial, Dean A. Fennell, FRCP, PhD, Director of the Mesothelioma Research Program and Chair of Thoracic Oncology at The University of Leicester and University Hospitals of Leicester, United Kingdom, noted the combination of nivolumab and ipilimumab has been...
Nivolumab Plus Ipilimumab: New Standard of Care in First-Line Treatment of Unresectable Malignant Pleural Mesothelioma?
Immunotherapy is taking on yet another highly aggressive cancer and yielding strong results, according to data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual Presidential Symposium.1 A prespecified interim analysis of the...
How Delays in Screening and Early Cancer Diagnosis Amid the COVID-19 Pandemic May Result in Increased Cancer Mortality
Earlier this year, as the COVID-19 pandemic was spreading across the United States, federal health officials and cancer societies urged Americans to delay routine cancer screenings and other elective procedures to keep them out of clinics to avoid potential exposure to the coronavirus and to...
Carfilzomib vs Bortezomib, Each Combined With Lenalidomide/Dexamethasone, in Newly Diagnosed Patients With Multiple Myeloma
As reported in The Lancet Oncology by Shaji K. Kumar, MD, and colleagues, the phase III ENDURANCE trial has shown no improvement in progression-free survival with carfilzomib plus lenalidomide/dexamethasone (KRd) vs bortezomib plus lenalidomide/dexamethasone (VRd) in patients with newly diagnosed...
American College of Surgeons Launches New Cancer Surgery Standards Program to Improve Quality of Care
The American College of Surgeons Cancer Programs recently launched the Cancer Surgery Standards Program (CSSP), a new initiative that aims to improve the quality of surgical care provided to patients with cancer by implementing standards for cancer surgery and standardizing the way operative data...
Lymphomas in Adolescents and Young Adults Deserve Further Study
Adolescents and young adults (AYAs) with lymphoma are a unique population, with distinct biology, disparities in outcome, poorer survival compared with children and adults, and variable impacts of treatments. Ongoing research on this patient population with lymphoma will hopefully lead to improved...
Fine-Tuning CAR T-Cell Therapy for Lymphomas
Chimeric antigen receptor (CAR) T-cell therapies are a major advance in the treatment of hematologic malignancies and are making inroads in solid tumors, but there is room for improvement in their design, since not all patients respond, and those who do may relapse. Researchers are studying...
Quality-Adjusted Progression-Free Survival and Time Without Symptoms or Toxicity in the ARIEL3 Trial of Rucaparib Maintenance Therapy for Recurrent Ovarian Cancer
In an exploratory post hoc analysis reported in the Journal of Clinical Oncology, Amit M. Oza, MD, and colleagues found superior quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with platinum-sensitive, recurrent...
CLL14 Trial Follow-up: Venetoclax Plus Obinutuzumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia
As reported in The Lancet Oncology by Al-Sawaf et al, 3-year follow-up of the phase III CLL14 trial showed maintained significant improvement in progression-free survival with the fixed-duration regimen of venetoclax/obinutuzumab vs chlorambucil/obinutuzumab in previously untreated patients with...
Selective MET Inhibitor Tepotinib in Patients With Advanced NSCLC and MET Exon 14–Skipping Mutation
As reported in The New England Journal of Medicine by Paul K. Paik, MD, and colleagues, the phase II VISION trial has shown durable responses with the highly selective MET inhibitor tepotinib in patients with non–small cell lung cancer (NSCLC) and MET exon 14–skipping mutation. As noted by the...
Osimertinib vs Platinum/Pemetrexed and Overall Survival in Patients With EGFR T790M Advanced NSCLC: AURA3 Trial
In patients with epidermal growth factor receptor (EGFR) T790M advanced non–small cell lung cancer (NSCLC), no statistically significant benefit in overall survival was observed with osimertinib vs pemetrexed plus carboplatin/cisplatin (platinum/pemetrexed) treatment, which possibly reflects the...
Long-Term Outcomes With Accelerated Partial-Breast vs Whole-Breast Irradiation in Patients With Early Breast Cancer
As reported in the Journal of Clinical Oncology by Icro Meattini, MD, and colleagues, 10-year follow-up of the Italian single-center APBI-IMRT-Florence trial showed no differences in ipsilateral recurrence or survival with accelerated partial-breast irradiation vs whole-breast irradiation after...
Updated Results of the ALTERNATIVE Trial of Lapatinib/Trastuzumab Plus AI in HER2-Positive, HR-Positive Metastatic Breast Cancer
Updated results of the phase III ALTERNATIVE trial of dual HER2 inhibition with lapatinib/trastuzumab plus aromatase inhibitor (AI) therapy in HER2-positive, hormone receptor (HR)-positive metastatic breast cancer were reported in the Journal of Clinical Oncology by Johnston et al. The previously...
American Cancer Society Updates Guideline for Cervical Cancer Screening
An updated cervical cancer screening guideline from the American Cancer Society has called for less—and more simplified—screening. The guideline was published by Elizabeth T.H. Fontham, MPH, DrPH, of Louisiana State University School of Public Health, New Orleans, and colleagues in CA: A Cancer...
Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer
Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...
Lenvatinib/Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, findings from a phase Ib/II trial indicate that the combination of lenvatinib and pembrolizumab is active in patients with previously treated advanced...
Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma
Combining the HER2-targeted therapy trastuzumab with carboplatin and paclitaxel improved survival rates for women with a rare, aggressive type of endometrial cancer, according to findings published by Amanda N. Fader, MD, of Johns Hopkins School of Medicine, Baltimore, and colleagues in Clinical...
LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer
As reported in The Lancet Oncology by Michael Frumovitz, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for...
PORTEC-3: Effect of Molecular Classification of Endometrial Cancer on Outcomes With Adjuvant Therapy
In a study reported in the Journal of Clinical Oncology, Alicia Léon-Castillo, MD, of Leiden University Medical Center, the Netherlands, and colleagues identified outcomes associated with molecular subgroups of patients with high-risk endometrial cancer enrolled in the PORTEC-3 trial of adjuvant...
SGO 2020: WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma
Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series. The initial ...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
ESMO 2019: Immunotherapy in Cervical and Endometrial Cancers
In studies reported at the ESMO Congress 2019, immunotherapy yielded encouraging outcomes in two gynecologic cancer populations in need of new treatments, including patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer....
SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
ASCO20: Cediranib Plus Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however,...
KEYNOTE-100: In Women With Advanced Ovarian Cancer, Pembrolizumab Yields Modest Antitumor Efficacy
the final results of the phase II KEYNOTE-100 study of pembrolizumab in women with advanced and recurrent ovarian cancer showed that pembrolizumab monotherapy produced modest clinical activity. Ursula Matulonis, MD, of Dana-Farber Cancer Institute, Harvard Medical School, reported the data at the...
ASCO20: Final Overall Survival Analysis From SOLO2 in Ovarian Cancer
For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...
Expert Point of View: Robert L. Coleman, MD
Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...
ASCO20: Secondary Surgery May Extend Survival in Recurrent Ovarian Cancer
Two phase III trials provided support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the...
ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Ovarian Cancer
In the phase III VELIA/GOG-3005 trial—reported at the European Society for Medical Oncology (ESMO) Congress 20191 and simultaneously published in The New England Journal of Medicine2—Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the ...
ESMO 2019: PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets
In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a...
Novel Drug Approvals and New Indications for Gynecologic Cancers
A number of new drugs and novel indications were added to the treatment armamentarium for gynecologic cancers over the past year. The U.S. Food and Drug Administration (FDA) approvals are noted here. Olaparib, PARP Inhibitor On May 8, 2020, the FDA expanded the indication of olaparib (Lynparza) to...
